Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

ate was higher in Q3 2009 compared to the same period in 2008 principally as a result of the recognition of valuation allowances against certain EU deferred tax assets and increases to accrued interest on tax contingencies in the third quarter of 2009. The adverse rate impact of these items was partially offset by foreign exchange gains on the retranslation of certain deferred tax assets, together with the benefit of tax return to provision adjustments following the submission of various tax returns in Q3 2009.

Equity in earnings of equity method investees

Equity in earnings of equity method investees of $0.6 million were recorded for the three months to September 30, 2009 (2008: $1.6 million). This comprised earnings of $1.4 million from the 50% share of the anti-viral commercialization partnership with GSK in Canada (2008: $1.6 million earnings) and losses of $0.8 million, being the Company's share of losses in the GeneChem, AgeChem and EGS Funds (2008: $nil).

    Unaudited US GAAP results for the three months and nine months to
    September 30, 2009 Consolidated Balance Sheets

                                                  September 30,  December 31,
                                                          2009          2008
                                                            $M            $M
    ASSETS
    Current assets:
    Cash and cash equivalents                            332.7         218.2
    Restricted cash                                       39.3          29.2
    Accounts receivable, net                             539.2         395.0
    Inventories                                          173.3         154.5
    Assets held for sale                                   1.7          16.6
    Deferred tax asset                                    99.8          89.5
    Prepaid expenses and other current assets            149.2         141.4

    Total current assets                               
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Addrenex Pharmaceuticals today expanded its pipeline of ... of an agreement to license a new drug ... debilitating sleep disorder, as well as other neurologic ... Addrenex the worldwide rights (excluding East Asia) to ...
... Circassia Ltd, a specialty,biopharmaceutical company focused on allergy, ... clinical development programme for its ragweed allergy,therapy. The ... based on Circassia,s ToleroMune(R) technology, which has previously,achieved ... allergies. Ragweed,is one of the leading causes of ...
Cached Medicine Technology:Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 2Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 3Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... risk of unintentionally overdosing on over-the-counter (OTC) pain medication, ... Dr. Michael Wolf, from Northwestern University in Chicago, and ... potential misuse of pain medication containing the active ingredient ... online in the Journal of General Internal Medicine ...
... Patricia Dickson, M.D., principal investigator at The Los ... BioMed), is co-principal investigator of a project that was ... Institute for Regenerative Medicine (CIRM). The goal of ... therapy for the treatment of mucopolysaccharidosis I (MPS I), ...
... TUESDAY, May 29 (HealthDay News) -- If you want to ... say researchers who have found that centenarians are often extroverts ... The findings stem from the Longevity Genes Project, launched ... City. All the participants in the latest study were over ...
... of methotrexate (MTX) safety data found that injection ... superior to oral therapy in long-term treatment of ... in Arthritis Care & Research , a ... (ACR), suggest that with similar efficacy and tolerability ...
... A popular European fitness routine called Nordic walking improves the ... study. In Nordic walking, people walk with poles and ... skiing. This fast-growing form of exercise in Europe is safe ... quality of life and reduces their risk of hospitalization, but ...
... STANFORD, Calif. A specific antioxidant supplement may be ... to a pilot trial from the Stanford University School ... 31 children with the disorder. The antioxidant, called ... as well as reducing the children,s repetitive behaviors. The ...
Cached Medicine News:Health News:Misuse of over-the-counter pain medication is potential health threat 2Health News:LA BioMed's Dr. Patricia Dickson researching treatments for neurodegenerative disorders 2Health News:Optimism, Laughter May Bring Long Life 2Health News:Optimism, Laughter May Bring Long Life 3Health News:Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment 2Health News:'Nordic Walking' a Winner for Heart Failure Patients, Study Says 2Health News:Antioxidant shows promise as treatment for certain features of autism, Stanford study finds 2Health News:Antioxidant shows promise as treatment for certain features of autism, Stanford study finds 3
Used for arthroscopic or open shoulder surgery. Powered positioning of back section inclines from 0 degrees to 90 degrees. Removable shoulder panels provide an eight-inch (203-mm) access area behind ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... an important part in our daily lives. ... changes can cause severe handicaps. A decisive ... prostheses was to produce a reconstructed joint ... as nearly possible.,The cementless RM Finger System ...
... the use of sand bags under the drape during ... shaped for optimal foot contact and positioning the leg ... be used under the drape by attaching it to ... for use on top of the drape. It can ...
Medicine Products: